Rezidiviertes MM: Carfilzomib-Triplett verbessert Lebensqualität

Blood Spotlight Carfilzomib

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the comple...

Lärm, Luft, Grün und Lebensqualität - Feldforschung in Salzburg-Lehen

Geoinformatik/GIScience beschäftigt zunehmend die Diagnose gesundheitserhaltender städtischer Umwelt. Für Salzburg existiert ein Indikatorennetz objektiver Umweltqualität, das nun durch subjektive Wahrnehmungen ergänzt wird. Das Feldprojekt QualAIRty von Geoinformatik und Umweltpsychologie befragte im Sommer 2014 im Stadtteil Lehen Passanten an vier qualitativ unterschiedlichen Standorten. Para...

Mm Mm^ Fl

Ein Expertensystem verbessert die Qualität der medizinischen Praxis

The knowledge base fort he practice of medicine is growing exponentially. To digest the available new information, a practitioner had to read almost all of his time and would not be able to treat patients. Since the economic burden is pressing doctors to see more patients in a shortage of time, the quality of the so-called evidence based medicine in practical medicine is declining. Additionally...

Carfilzomib: a novel agent for multiple myeloma.

OBJECTIVES Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma (MM). This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and administration of carfilzomib, and its role in treating MM patients. KEY FINDINGS Carfilzomib is a selective proteasome inhibitor that differs struc...